“To your question on, you know, kinda next year, yeah, I expect to see another real strong year of growth in in The US with additional demand coming from the from the new, from the new sensor the new dual analyte sensor.”

In context

“and running. So that caused back orders with customers, it caused back orders to wholesalers at the pharmacy channel. The way we had planned this year was our site would come up and running and it would be more of a linear kind of recovery But the factory actually did really well in the first half. So that led to customers doing some restocking earlier than what we had bought. And a little bit higher quite frankly just given the demand that they were seeing in in Libre three. So that resulted in a little bit of a pull forward of a couple percentage points. Of growth. So I think it's just a little bit of a timing dynamic. I think most importantly we remain on track with the original U. S. Full year growth assumption of over 20%. So demand is still very, very strong. And we're seeing that. To your question on, you know, kinda next year, yeah, I expect to see another real strong year of growth in in The US with additional demand coming from the from the new, from the new sensor the new dual analyte sensor. I think that's gonna help drive increasing penetration, in that intensive in user segment. So I'd say, there's still room for penetration I would say, in that segment. In The US, it's there's still some rum also, but I'd say gonna really help us drive drive share gains. Whether it's in you know, pumper in the pumper segment or just in general intensive insulin user segments. There's still a lot of penetration in the basal segment I mean, I know because of the dual analyte sensor, we get a lot of attention on this insulin, intensive insulin segment. But I'm still very bullish on the basal segment. In The US, it's only about 20% penetrated today. Internationally, it's only 5% it's less than 5%. So I think there's still a lot of opportunity for growth in The U. S. With continued basal penetr”